NDRA - CONSENSUS CO - ENDRA Life Sciences

The price trend reflected in this chart confirms the status of ENDRA Life Sciences (NDRA) as an authoritative developer of safe steatosis visualization methods. The company creates TAEUS thermoacoustic systems, where AI automates real-time tissue analysis. The current figure stands at 24.96, however, low initial equipment sales volumes increase expenses, which temporarily restricts the growth of software operating margins.

ENDRA Life Sciences is transforming liver fat diagnostics by replacing invasive biopsies with painless ultrasound scanning. The aggregate analyst price target accumulates expert forecasts for the asset's value, reflecting market expectations for the commercialization of this technology; an upward trend in this vector signals a re-evaluation of the company's fundamental potential, allowing investors to synchronize their entry point with the professional community consensus.